IonQ and CCRM join forces for quantum-biotech collaboration

IonQ and CCRM have joined forces in a groundbreaking partnership to advance the development of cutting-edge therapeutic solutions by leveraging the power of quantum and quantum-AI technologies. This collaboration marks an exciting step in the field of regenerative medicine, with IonQ committing to investing in CCRM’s innovative quantum-biotech initiatives. By solidifying IonQ as the primary technology partner within CCRM’s extensive global network of advanced therapy hubs, both organizations aim to revolutionize therapeutic development through computational innovation.

CCRM, a prominent figure in the realm of advanced therapies, boasts over 100,000 square feet of top-tier good manufacturing practice (GMP) facilities, along with a team of 300+ accomplished scientific professionals. Established in Toronto, Canada, in 2011, CCRM has been dedicated to realizing the full potential of regenerative medicine to provide lasting treatments for chronic diseases worldwide. Through collaborations with academia, industry partners, and investors on a global scale, CCRM is committed to pushing the boundaries of therapeutic innovation.

Niccolo de Masi, the Chairman and CEO of IonQ, expressed his enthusiasm for the partnership, highlighting the transformative possibilities within the healthcare sector. By aligning with CCRM and its network of partners, IonQ aims to pioneer groundbreaking applications that enhance therapeutic development, biomanufacturing, and treatment delivery on a global scale. Together, the two organizations will focus on optimizing bioprocesses, disease modeling workflows, and quantum-enhanced simulations to support the creation of advanced therapies with unparalleled precision and efficacy.

The collaboration between IonQ and CCRM is set to embark on initial projects in Canada and Sweden in 2026, focusing on solving some of the most critical challenges in healthcare and life sciences. Michael May, President and CEO of CCRM, emphasized the unique capabilities that this partnership brings to the table, stating that it opens up new avenues for accelerating the discovery and application of advanced therapies to benefit patients worldwide. Similarly, Fredrik Wessberg, CEO of CCRM Nordic, noted the shared commitment between Canada and Sweden to prioritize advancements in advanced therapies and quantum computing, underscoring the importance of global collaboration in delivering complex healthcare solutions.

Building on its previous collaborations, IonQ recently partnered with AstraZeneca to establish a quantum application development center in Sweden, expanding its reach into the realm of quantum technology. The company has also made significant strides in bolstering its R&D capabilities and quantum engineering teams, with a focus on driving innovation in drug discovery, materials science, financial modeling, cybersecurity, and defense. IonQ’s commitment to advancing quantum networking positions the company as a frontrunner in developing the quantum internet infrastructure, paving the way for transformative advancements in various industries.

IonQ’s remarkable progress and innovative technology have garnered recognition in esteemed rankings such as Fortune Future 50, Newsweek’s 2025 Excellence Index 1000, and Forbes’ 2025 Most Successful Mid-Cap Companies list. With a vision to deliver the world’s most powerful quantum computers boasting 2 million qubits by 2030, IonQ is poised to revolutionize the landscape of quantum computing and make this cutting-edge technology more accessible and impactful than ever before.